Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Barbara Baggstrom

Nurse Practitioner Randolph, NJ Nurse Practitioner

NPI 1104894989 CMS profile 10663821

765 Route 10 E, Ste 203, Randolph, NJ 07869

Open in the dashboard

General payments

$3,290

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barbara Baggstrom of Randolph, NJ is reported in the CMS Open Payments database as having received $3,290 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $281 16
2024 General $843 46
2023 General $636 34
2022 General $729 46
2021 General $801 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Baggstrom
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Barbara Baggstrom were reported at $281. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Barbara Baggstrom Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $801 $135 $40–$426 $132
2022 $729 $152 $48–$470 $149
2023 $636 $166 $54–$529 $160
2024 $843 $173 $55–$556 $164
2025 $281 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $451 15 payments
  2. Supernus Pharmaceuticals, Inc. $343 15 payments
  3. kaleo, Inc. $278 19 payments
  4. Merck Sharp & Dohme Corporation $237 16 payments
  5. Neos Therapeutics, LP $234 17 payments
  6. Corium, Inc. $232 15 payments
  7. Pfizer Inc. $185 12 payments
  8. Tris Pharma Inc $177 12 payments
  9. AbbVie, Inc. $168 11 payments
  10. Sanofi Pasteur Inc. $137 7 payments
  11. Other $850 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,290 192 payments
Products named General payments · program years 2021–2025
  1. BEXSERO $451 15 payments
  2. QELBREE $303 13 payments
  3. AUVI-Q $243 17 payments
  4. GARDASIL 9 $237 16 payments
  5. Azstarys $232 15 payments
  6. VAXELIS $224 15 payments
  7. Adzenys XR-ODT $181 15 payments
  8. COTEMPLA XR-ODT $175 12 payments
  9. LUPRON DEPOT $168 11 payments
  10. JORNAY PM $131 9 payments
  11. Other $2,092 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record